Papadopoulos V, Berkovich A, Krueger K E, Costa E, Guidotti A
Department of Anatomy and Cell Biology, Georgetown University School of Medicine, Washington, D.C. 20007.
Endocrinology. 1991 Sep;129(3):1481-8. doi: 10.1210/endo-129-3-1481.
A recognition site for benzodiazepines structurally different from that linked to various gamma-aminobutyric acid A (GABAA) receptor subtypes is located on the outer mitochondrial membranes of steroidogenic cells. This protein has been signified to be important in the regulation of steroid biosynthesis. Because of its location it is designated herein as the mitochondrial benzodiazepine receptor (MBR). A putative endogenous ligand for MBR is the peptide diazepam binding inhibitor (DBI), previously shown to displace drugs from MBR and to be expressed and stored in steroidogenic cells rich in MBR. The two model systems used to study steroidogenic regulation by DBI were the Y-1 adrenocortical and MA-10 Leydig cell lines previously shown to be applicable in studies of mitochondrial steroidogenesis. Both cell lines contain DBI as well as DBI processing products, including the DBI fragments that on reverse phase HPLC coelute with the naturally occurring triakontatetraneuropeptide [TTN; DBI-(17-50)] and octadecaneuropeptide [DBI-(33-50)]. When DBI purified from rat brain was added to mitochondria prepared from Y-1 and MA-10 cell lines, it increased the rates of pregnenolone formation in a dose-related manner. In both cell lines, maximal stimulation (3-fold) of mitochondrial steroidogenesis was obtained with 0.33 microM DBI, with an EC50 of approximately 0.1 microM. However, DBI concentrations higher than 1 microM caused a smaller increase in pregnenolone formation. Flunitrazepam, a benzodiazepine that binds with high nanomolar affinity to MBR, was recently shown to act as an antagonist of ACTH and LH/hCG-induced steroidogenesis and was found in the present studies to inhibit DBI-stimulated mitochondrial steroidogenesis. During the incubation with mitochondria, DBI was partially processed to different peptide fragments, including octadecaneuropeptide and TTN. To determine whether DBI processing products influence mitochondrial steroid biosynthesis, several DBI fragments and other peptides structurally unrelated to DBI were tested. Among these, only TTN stimulated mitochondrial steroid synthesis in a dose-dependent manner similar to DBI.
苯二氮䓬类药物的识别位点在结构上不同于与各种γ-氨基丁酸A(GABAA)受体亚型相关的位点,它位于类固醇生成细胞的线粒体外膜上。这种蛋白质在类固醇生物合成的调节中具有重要意义。由于其位置,本文将其命名为线粒体苯二氮䓬受体(MBR)。MBR的一种假定内源性配体是肽类地西泮结合抑制剂(DBI),先前已证明它能将药物从MBR上置换下来,并在富含MBR的类固醇生成细胞中表达和储存。用于研究DBI对类固醇生成调节作用的两个模型系统是Y-1肾上腺皮质细胞系和MA-10睾丸间质细胞系,先前已证明它们适用于线粒体类固醇生成的研究。这两种细胞系都含有DBI以及DBI加工产物,包括在反相高效液相色谱中与天然存在的三十四肽[TTN;DBI-(17-50)]和十八肽[DBI-(33-50)]共洗脱的DBI片段。当将从大鼠脑中纯化的DBI添加到从Y-1和MA-10细胞系制备的线粒体中时,它以剂量相关的方式提高了孕烯醇酮的生成速率。在这两种细胞系中,用0.33微摩尔/升的DBI可获得线粒体类固醇生成的最大刺激(3倍),半数有效浓度(EC50)约为0.1微摩尔/升。然而,高于1微摩尔/升的DBI浓度导致孕烯醇酮生成的增加较小。氟硝西泮是一种与MBR具有高纳摩尔亲和力结合的苯二氮䓬类药物,最近已证明它可作为促肾上腺皮质激素(ACTH)和促黄体生成素/人绒毛膜促性腺激素(LH/hCG)诱导的类固醇生成的拮抗剂,并且在本研究中发现它可抑制DBI刺激的线粒体类固醇生成。在与线粒体孵育期间,DBI被部分加工成不同的肽片段,包括十八肽和TTN。为了确定DBI加工产物是否影响线粒体类固醇生物合成,测试了几种DBI片段和其他与DBI结构无关的肽。其中,只有TTN以类似于DBI的剂量依赖性方式刺激线粒体类固醇合成。